Respiro Diagnostics, a UK-based startup, is developing breath-based diagnostics for lung diseases. The company has secured £1 million in a pre-seed funding round to advance its technology.
The round was led by Zinc Venture Capital and SFC Capital. The exact valuation and terms of the deal were not disclosed by the sources.
The startup operates in the growing diagnostic technology market, where non-invasive methods are gaining traction. Its breath analysis approach could offer a faster, simpler alternative to traditional lung function tests or biopsies.
This funding signals continued investor interest in early-stage health tech, particularly in respiratory diagnostics. The pre-seed round gives Respiro capital to pursue product development and initial clinical validation.
The company did not provide specific timeline details for its next development milestones.
A counter argument to consider is that breath-based diagnostics have historically struggled to achieve the sensitivity and specificity required for clinical adoption. Competing technologies from larger firms may also challenge Respiro's market entry. AI context: This brief was composed from a single source with verified trust rating. The content is limited to the details provided in the article; no additional verification or independent sourcing was available.